The study found that lifetime risk of developing breast cancer ranges from less than 1% in low-income countries to over 16% in wealthier nations. The risk of dying from breast cancer varies dramatically across regions, with very high HDI countries having the highest lifetime risk at 10.37%.
A global study estimates the lifetime risk of developing and dying from colorectal cancer, revealing stark disparities by country, sex, and age. The study's findings highlight the need for tailored prevention and screening strategies, with a focus on high-HDI countries and low-resource settings.
This special issue of Cancer Biology & Medicine presents a comprehensive snapshot of global cancer incidence and mortality, highlighting emerging trends and risk factors. The collection offers actionable insights for prevention and early detection, leveraging large-scale population data and innovative analytical frameworks.
The gut microbiome is recognized as a key driver of tumor initiation and progression, with microbial dysbiosis fueling malignancy or enhancing anti-tumor immunity. Microbiome science and cancer biology are converging to develop new strategies for prevention, diagnosis, and therapy.
Researchers classified breast cancer patients into three distinct subtypes based on the cancer-immunity cycle (CIC), predicting patient response to immunotherapy. The CIC score measures six key steps in the anti-tumor immune response, identifying new therapeutic targets and potential combination strategies.
Cancer cells develop multiple resistance mechanisms to antibody-drug conjugates, including antigen downregulation and mutation, internalization deficits, and payload efflux. Researchers propose innovative strategies, such as bispecific ADCs, dual-payload designs, and combination regimens, to overcome these defenses.
Research reveals two distinctly different microbial worlds in colorectal cancer, one for left- and right-sided tumors. The study found that the mucosal microbiome varies dramatically depending on tumor location, opening possibilities for microbiome-based diagnostics and personalized treatment approaches.
Researchers discover microbes can induce immunogenic cell death, activating immune system against tumors. This process transforms immunologically 'cold,' therapy-resistant tumors into 'hot,' responsive ones by triggering damage-associated molecular patterns (DAMPs).
Researchers developed a theranostic system that combines imaging and therapy using click chemistry, allowing real-time treatment monitoring and targeted drug delivery. This approach promises to reduce toxic side effects and improve patient outcomes by enabling on-demand drug activation directly at the disease site.
Researchers review how engineered nanomaterials can be used to deliver antigens, improve antigen presentation, support T cell priming and infiltration, and reshape tumor niches. The materials are designed to intervene across the cancer-immunity cycle, improving immune activation while reducing off-target effects.
Research suggests that tumors with poor prognosis outcomes may be infected with bacteria, which can weaken treatment by altering local immunity and damaging tissue structure. The authors propose using familiar carrier-free antibiotic and chemotherapeutic drug combinations to restore treatment sensitivity in these tumors.
The special issue highlights how nanotechnology is being used to improve drug targeting, immunotherapy synergy, and tumor microenvironment reprogramming. It showcases cutting-edge research on postbiotics, click chemistry-driven theranostics, and tumor biomineralization as emerging bioactive agents.
A new study combines dynamic full-field optical coherence tomography with deep learning to generate real-time virtual pathology images of fresh lymph nodes during surgery. The approach achieved high accuracy and sensitivity, reducing tissue consumption and manual workload.
A new AI framework combines digital pathology and structured clinical data to predict PIK3CA mutation status in breast cancer. The Multimodal PIK3CA Model outperformed single-modality models, achieving an AUC of 0.745, with strong performance across multiple clinical datasets.
Researchers have discovered two therapeutic vulnerabilities in LAR triple-negative breast cancer: ERBB2 mutations and senescence. Targeting these weaknesses with next-generation TKIs and immunotherapy could improve patient outcomes.
International guidelines must be tailored to address diverse biological behaviors of breast cancer subtypes and regional healthcare infrastructure limitations. Precision medicine, supported by molecular subtyping and AI, is refining these guidelines for personalized and effective care.
Researchers found that BEX2 levels were associated with weaker stemness, reduced tumor-forming ability, lower drug resistance, and less invasive behavior. BEX2 destabilizes MCL1, dampening Hedgehog signaling, a pathway closely tied to cancer stem cell maintenance.
A recent review highlights differences in gastric cancer immunotherapy outcomes among various populations, particularly between Asian and non-Asian patients. The study suggests that treatment responses may be influenced by factors such as tumor biology, host immunity, infection, and environmental exposures.
Researchers have developed microfluidic platforms that capture dynamic cell behavior and reveal how cancers evade immunity, how therapies succeed or fail. These systems can test cellular therapies, identify biomarkers, and support personalized cancer treatment.
Researchers discovered that migration and invasion inhibitory protein (MIIP) suppresses colorectal cancer progression by preventing immune cells from adopting tumor-supportive behaviors. MIIP reduces cancer cell migration, invasion, and metastasis by interrupting an immune feedback loop involving STING, NFκB2, and IL-10.
Emerging research reveals the gut microbiota plays a decisive role in shaping treatment outcomes for cancer immunotherapy. Beneficial bacteria enhance anti-tumor immunity by producing immune-active metabolites and activating key immune cells.
A new study reveals that STING agonists can directly trigger tumor cell death in nervous system cancers by activating an intrinsic molecular pathway inside cancer cells themselves. The research identifies HMGN2 as a key candidate promoting apoptosis and suppressing tumor growth.
A new study maps breast cancer vulnerabilities, identifying two major classes of weaknesses: gene addiction and synthetic lethality. The analysis highlights key metabolic and signaling dependencies that distinguish different subtypes, revealing actionable targets for precision treatment strategies.
Researchers highlight how minimal residual disease detection is changing breast cancer management by capturing molecular traces of cancer at extremely low levels. CTDNA-based monitoring reveals relapse risk months ahead of clinical symptoms, enabling clinicians to identify high-risk patients and adjust treatment strategies in real time.
Researchers have made significant progress in treating non-small cell lung cancer (NSCLC) with targeted therapies, including tyrosine kinase inhibitors (TKIs) that target specific gene mutations. These treatments have shown effectiveness across various patient groups and improved outcomes for those with actionable mutations.
Tumor-specific MHC-II expression is a critical driver of antitumor responses, modulating CD4⁺ T-cell priming, differentiation, and memory formation. This review highlights MHC-II as a promising biomarker and therapeutic target for next-generation cancer treatments.
A special issue of Cancer Biology & Medicine highlights scientific progress, policy innovations, and digital health tools to accelerate cervical cancer elimination. The collection provides a comprehensive resource for advancing women's health equity worldwide, tackling vast inequities in health resources and implementation capacity.
Researchers are developing neoantigen-based dendritic cell vaccines that aim to train the immune system to recognize tumor-specific mutations and trigger targeted immune responses against cancer cells. Clinical trials have shown promising results, with patient-derived DC vaccines triggering strong, durable immune responses, delaying tu...
A study of 168 patients with ampullary adenocarcinoma reveals that the pancreatobiliary signature and blood vessel invasion are independent indicators of poor outcomes. Tumor deposits are identified as a crucial context-dependent biomarker, predicting who benefits from adjuvant chemotherapy.
Despite progress in controlling stomach, liver, and esophageal cancers, China's total cancer deaths continue to rise, projected to reach 2.4 million by 2030. Population aging and unequal access to healthcare drive these increases, with rural areas lagging behind urban regions.
A new AI-driven platform, Intelligent Digital Education Tool for Colposcopy (iDECO), has been developed to bridge training gaps in cervical cancer prevention. The platform uses real clinical cases, gamified learning, and personalized analytics to enhance diagnostic accuracy and decision-making among medical professionals.
Researchers use mathematical modeling to estimate how vaccination, screening, and treatment collectively drive elimination. Studies show that with sustained investment and policy coordination, cervical cancer could be eliminated within decades in high-income countries and within the next century globally. The models also reveal cost-ef...
A study of over 3,000 patients identified molecular hallmarks driving hyper-progression recurrence in liver cancer, enabling tailored surgical decisions and targeted therapies. Predictive models and nomograms stratify patients before and after surgery, guiding more effective strategies.
Chinese researchers contribute to global cervical cancer prevention with affordable HPV vaccines, self-sampling methods, triaging strategies, and AI-assisted screening. These innovations offer scalable solutions to accelerate progress toward eliminating cervical cancer worldwide.
A recent study analyzed cervical cancer data from 2000 to 2020, revealing a tripling of age-standardized incidence between 2000 and 2016 before plateauing. The findings highlight widening disparities by age and geography, threatening elimination targets.
A digital platform developed by Tencent Inclusive Health Lab enhances population-based cervical cancer screening, reducing over-screening by 98% and improving detection of high-grade precancerous lesions. The system streamlines patient identification, reduces unnecessary testing, and strengthens follow-up and treatment adherence.
A special issue of Cancer Biology & Medicine brings together experts to accelerate cervical cancer elimination, highlighting scientific advances, policy innovations, and equity efforts. The journal's mission bridges oncology research with public health priorities.
Tiny organoid models capture the complexity of human tumors, enabling accurate testing of drugs and prediction of treatment responses. These mini-tumors preserve tumor heterogeneity, reflect real patient biology, and provide a platform for personalized cancer vaccines.
A new study links H. pylori infection to gastric cancer progression through consistent protein markers, including OLFM4 and ENO1, which stratify patients by cancer risk. The findings provide insights into the biology of infection-induced carcinogenesis and offer potential biomarkers for early detection.
PANoptosis, a hybrid form of cell death, is being explored as a strategy to tackle liver cancer. By integrating apoptosis, pyroptosis, and necroptosis pathways, PANoptosis triggers both direct tumor killing and immune reprogramming.
Breakthroughs in targeting KRAS, including promising drugs like MRTX1133 and RMC-9805, offer new hope for pancreatic cancer patients. The study explores emerging tools like PROTAC-based degraders and combination therapies involving MEK, PI3K, or CDK4/6 inhibitors to address drug resistance.
The study reveals how tumors manipulate amino acid metabolism to gain a competitive edge, starving immune cells and reshaping the tumor immune microenvironment. Amino acids, once seen as passive nutrients, are now known to steer cell fate, immune suppression, and resistance to immunotherapy.
Breast cancer's reliance on lactate metabolism drives tumor progression, immune evasion, and metastasis. Researchers propose targeting lactate production and lactylation to develop more precise treatments with improved survival rates.
A new blood test, PIPscore, has been developed to predict the efficacy of immunotherapy in triple-negative breast cancer (TNBC) patients. The test analyzes plasma proteins and achieved high accuracy in forecasting patient responses.
Senescent macrophages, once thought to be passive bystanders, actively drive tumor development through inflammatory signals and immune suppression. Targeting these cells with senolytics, senomorphics, and senoreverters may offer new possibilities for cancer therapy.
New research reveals neutrophils' complex role in cancer, with both pro-tumor and anti-tumor effects. Understanding their plasticity is crucial for developing novel therapeutic strategies that harness their anti-tumor potential.
A study published in Cancer Biology & Medicine found that combining mitochondrial transplantation with cisplatin enhances immune cell infiltration, reverses tumor metabolism, and improves the effectiveness of chemotherapy. This innovative approach shows potential to reshape how lung tumors are treated.
A new review integrates advances from genomics, transcriptomics, epigenomics, proteomics, metabolomics, and microbiomics to understand colorectal cancer's progression to the liver. The study identifies potential biomarkers and therapeutic targets, offering fresh hope for improving diagnosis and treatment outcomes.
Researchers have discovered a hidden switch in breast cancer that uncovers PHGDH's role as both a metabolic and transcriptional regulator. PHGDH suppresses genes vital for immune cell function, steering macrophages toward tumor-fighting behavior. The study offers promising new strategies for reprogramming the tumor microenvironment.
Researchers found that elevated L-aspartic acid levels predict gastric cancer risk, while influencing treatment outcomes of Helicobacter pylori eradication and garlic supplementation. This study suggests using plasma L-aspartic acid profiling to tailor prevention efforts and identify high-risk individuals.